Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
More medication means more foreign protein for the immune system to respond to, more volume displacing tissue, and more potential for a localized reaction
Heres what I found: Bariatric surgery leads to greater, more durable weight loss and comorbidity reduction compared to GLP-1s GLP-1s offer substantial but less sustained comorbidity benefit with higher discontinuation rates (up to 50% at 35 yrs) GLP-1s do not eliminate the need for bariatric surgery in severe obesity Total weight loss trends higher for bariatric surgery, and real-world GLP-1 effectiveness is generally lower than clinical trial results (a significant finding that deserves its own post) Bariatric surgery is generally more effective than GLP-1s for long-term diabetes remission and cardiovascular risk reduction GLP-1s are associated with higher ongoing costs and are less cost-effective than bariatric surgery long-term The take home: GLP-1s are a valuable addition but dont replace bariatric procedures for patients with severe obesity or those requiring durable, substantial weight loss with co-morbidity reduction
While oral formulations offer non-invasive dosing, their low bioavailability and potential gastrointestinal side effects have remained major limitations
Stratification by glycemic control showed no significant difference in PsA risk between the two groups, regardless of HbA1c levels in the year prior to the index date
